Advocacy intelligence hub — real-time data for patient organizations
Nordlandssykehuset HF — NA
Vanderbilt University Medical Center
Alnylam Pharmaceuticals
GIVLAARI: FDA approved
GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
GIVLAARI
(givosiran)Orphan drugAlnylam Pharmaceuticals, Inc.
12.1 Mechanism of Action Givosiran is a double-stranded small interfering RNA that causes degradation of aminolevulinate synthase 1 ( ALAS1 ) mRNA in ...
Karl E Anderson, MD
University of Texas
Eliane Sardh, MD PhD
Karolinska University Hospital, Stockholm
Karl E Anderson
University of Texas
Amy Simon, MD
Alnylam Pharmaceuticals
Nader Najafian, MD, MD
Alnylam Pharmaceuticals
📍 BOSTON, MA
Christer Andersson, MD
Umeå University